HSBC Holdings plc vs MiniMed Group Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while MiniMed Group Inc. Common Stock trades at $19.71 (market cap $5.57B). The key difference: HSBC Holdings plc is far larger — about 56× MiniMed Group Inc. Common Stock's market cap, and HSBC Holdings plc pays a 4.05% dividend while MiniMed Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and MiniMed Group Inc. Common Stock for 1 Days on average.
| HSBC | MMED | |
|---|---|---|
Market Cap | $311.92B | $5.57B |
Volume | 3,546,658 | 23,336,073 |
Sector | Financials | Health |
52-Week High | $107.86 | $23.84 |
52-Week Low | $65.67 | $10.80 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | $222.19B | $5.37B |
Dividend Yield | 4.05% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →